Ryoncil's commercial success is funding pipeline expansion without dilution, with a strong cash position and lower-cost debt refinancing. The next major catalyst is CLBP Phase 3 data in mid-2027; watch for updates on the adult aGvHD trial and BLA filings in the interim.
Price Chart
Executive Summary
Mesoblast provided an ASX CEO Connect presentation on June 2, 2026, highlighting the successful U.S. launch of Ryoncil, with net revenue exceeding US$100M since launch, Q3 FY26 net revenue of US$30.3M, and gross profit of US$44.2M in 1H FY26. The company also announced a new US$125M term loan replacing higher-cost debt, a cash balance of US$122M, and several upcoming Phase 3 milestones including top-line data for chronic low back pain trial in mid-CY2027.
Key Facts
- Ryoncil net revenue has exceeded US$100M since launch; Q3 FY26 net revenue was US$30.3M
- Ryoncil gross profit in 1H FY26 was US$44.2M, with direct selling costs of US$7.7M
- New US$125M term loan replaces existing higher-cost debt; cash balance US$122M at March 31, 2026
- Pivotal Phase 3 trial for chronic low back pain achieved patient recruitment target in April; top-line primary endpoint expected mid-CY2027
- Phase 3 IND for Duchenne Muscular Dystrophy cleared by FDA
Financial Impact
Ryoncil net revenue exceeded US$100M cumulative since launch; Q3 FY26 revenue US$30.3M; gross profit 1H FY26 US$44.2M
Risk Factors
- Clinical trial risks for Phase 3 programs, particularly CLBP and heart failure
- Dependence on continued Ryoncil revenue growth to fund operations without additional capital raises
- Potential competition from other MSC therapies entering the market
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000058 |
| Document: form6-kpressreleasecoverfi.htm | 0001345099-26-000058 |
| Document: 0001345099-26-000058-index-headers.html | 0001345099-26-000058 |
| Document: 0001345099-26-000058-index.html | 0001345099-26-000058 |
| Document: 0001345099-26-000058.txt | 0001345099-26-000058 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jun 10, 2026 19w ago | 6-K | $1.55 $1.55 | · 0.00% | ▼ −3.89% | $1.32 (−14.84%) |
Apr 30, 2026 25w ago | 6-K | $1.70 $1.70 | · 0.00% | ▼ −5.23% | $1.32 (−22.35%) |
Apr 16, 2026 27w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▲ +0.88% | $1.32 (−17.50%) |
Apr 15, 2026 27w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▲ +0.21% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
Apr 8, 2026 28w ago | 6-K | $1.60 $1.70 | ▲ +6.25% | ▼ −2.29% | $1.32 (−17.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers